Format

Send to

Choose Destination
Oncoimmunology. 2014 Jun 18;3:e29126. eCollection 2014.

BRAF-targeted therapy alters the functions of intratumoral CD4+ T cells to inhibit melanoma progression.

Author information

1
Department of Immunobiology; Yale University School of Medicine; New Haven, CT USA.
2
Department of Immunobiology; Yale University School of Medicine; New Haven, CT USA ; Howard Hughes Medical Institute; Chevy Chase, MD USA.

Abstract

The establishment of an immunosuppressive tumor microenvironment is a hallmark feature driving cancer cell evasion of immunosurveillance. In a murine melanoma model, we recently demonstrated that decreased intratumoral CD4+ T-cell expression of CD40L and interferon γ (IFNγ) is critical to maintain this immunosuppressive microenvironment. Altered effector functions of tumor-associated CD4+ T cells is essential for B-RafV600E inhibitor-mediated restoration of antitumor immunity.

KEYWORDS:

BRAF; CD40L; IFNγ; T cell; melanoma

Supplemental Content

Full text links

Icon for Taylor & Francis Icon for PubMed Central
Loading ...
Support Center